Investing.com - Twist Bioscience (NASDAQ: TWST) reported fourth quarter EPS of $-0.81, $0.11 better than the analyst estimate of $-0.92. Revenue for the quarter came in at $66.9M versus the consensus estimate of $63.35M.
Guidance
Twist Bioscience sees Q1 2024 revenue of $67.00M-$68.00M versus the analyst consensus of $62.97M.
Twist Bioscience sees FY 2024 revenue of $285.00M-$290.00M versus the analyst consensus of $241.50M.
Twist Bioscience's stock price closed at $19.07. It is down -1.60% in the last 3 months and down -23.14% in the last 12 months.
Twist Bioscience saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Twist Bioscience's stock price’s past reactions to earnings here.
According to InvestingPro, Twist Bioscience's Financial Health score is "good performance".
Check out Twist Bioscience's recent earnings performance, and Twist Bioscience's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar